Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.39 |
| ▸ | CCNC | P24863 | 4/20 | 0.38 |
| ▸ | CDK8 | P49336 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472115 | 0.88 | RXRA (0.44) | CNR1ALDH1A1KDM4ESCD5CCNC | |
| SCHEMBL2259079 | 0.84 | ROCK2 (0.46) | F10ALDH1A1KDM4ESCD5HSD17B10 | |
| SCHEMBL2260753 | 0.83 | CNR1 (0.43) | CNR1 | |
| SCHEMBL2256210 | 0.81 | HSP90AA1 (0.49) | F10SCD5 | |
| SCHEMBL12361716 | 0.79 | MEN1 (0.46) | CNR1F10ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3471554 | 0.78 | SCD5 (0.47) | CNR1SCD5HSD17B10SCD | |
| SCHEMBL2256415 | 0.78 | PDK2 (0.46) | CNR1F10ALDH1A1CNR2 | |
| SCHEMBL2260709 | 0.76 | TSHR (0.54) | ALDH1A1 | |
| SCHEMBL3474064 | 0.75 | RXRA (0.48) | CNR1CCNCCDK8 | |
| SCHEMBL3472851 | 0.75 | RXRA (0.51) | CNR1SCD5CCNCCDK8SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | CNR1 119/4885F10 143/4885ALDH1A1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.